Entrada Therapeutics Inc. outlined planned 2026 milestones across its pipeline, including multiple Duchenne muscular dystrophy programs and a partnered myotonic dystrophy type 1 program. The company highlighted expected clinical data readouts for ENTR-601-44 and ENTR-601-45 in 2026, anticipated regulatory progress for ENTR-601-50 and ENTR-601-51 by year-end 2026, and ongoing development of Vertex’s VX-670 with the multiple ascending dose portion expected to complete in mid-2026. Entrada also noted progress in inherited retinal diseases, including ENTR-801 for Usher syndrome type 2A and a second ocular program in lead optimization with candidate declaration expected in the second half of 2026. The presentation reported a cash balance of approximately $296 million as of year-end 2025 and a cash runway into Q3 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.